Compare AMPX & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPX | HCM |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.3B |
| IPO Year | 2022 | 2015 |
| Metric | AMPX | HCM |
|---|---|---|
| Price | $9.50 | $14.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | ★ $23.00 | $22.01 |
| AVG Volume (30 Days) | ★ 4.7M | 52.5K |
| Earning Date | 11-05-2026 | 07-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $73,011,000.00 | N/A |
| Revenue This Year | $92.62 | $14.24 |
| Revenue Next Year | $50.83 | $11.52 |
| P/E Ratio | ★ N/A | $5.49 |
| Revenue Growth | ★ 202.11 | N/A |
| 52 Week Low | $7.71 | $9.77 |
| 52 Week High | $24.23 | $16.33 |
| Indicator | AMPX | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 45.16 | 53.37 |
| Support Level | $9.30 | $13.70 |
| Resistance Level | $10.60 | $14.44 |
| Average True Range (ATR) | 0.51 | 0.30 |
| MACD | 0.03 | -0.09 |
| Stochastic Oscillator | 27.67 | 39.44 |
Amprius Technologies Inc is engaged in the production of silicon anodes for high-energy-density lithium-ion batteries. The company develops, manufactures and markets lithium-ion batteries for mobility applications, including the aviation, electric vehicle (EV) and light electric vehicle (LEV) industries. The company's batteries are used for existing and emerging aviation applications, including unmanned aerial systems, such as drones and high-altitude pseudo satellites. Its silicon anodes are a direct drop-in replacement of the graphite anode in traditional lithium-ion batteries, and its manufacturing processes leverage the manufacturing processes for conventional lithium-ion batteries and the related supply chain.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.